{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:03:34Z","timestamp":1776485014376,"version":"3.51.2"},"reference-count":105,"publisher":"Oxford University Press (OUP)","issue":"12","funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"Department of Health and Human Services","doi-asserted-by":"publisher","award":["75F40119F19001"],"award-info":[{"award-number":["75F40119F19001"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The US Food and Drug Administration (FDA) created the Sentinel System in response to a requirement in the FDA Amendments Act of 2007 that the agency establish a system for monitoring risks associated with drug and biologic products using data from disparate sources. The Sentinel System has completed hundreds of analyses, including many that have directly informed regulatory decisions. The Sentinel System also was designed to support a national infrastructure for a learning health system. Sentinel governance and guiding principles were designed to facilitate Sentinel\u2019s role as a national resource. The Sentinel System infrastructure now supports multiple non-FDA projects for stakeholders ranging from regulated industry to other federal agencies, international regulators, and academics. The Sentinel System is a working example of a learning health system that is expanding with the potential to create a global learning health system that can support medical product safety assessments and other research.<\/jats:p>","DOI":"10.1093\/jamia\/ocac153","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T11:43:37Z","timestamp":1662983017000},"page":"2191-2200","source":"Crossref","is-referenced-by-count":37,"title":["The US Food and Drug Administration Sentinel System: a national resource for a learning health system"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9340-7189","authenticated-orcid":false,"given":"Jeffrey S","family":"Brown","sequence":"first","affiliation":[{"name":"Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School , Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron B","family":"Mendelsohn","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School , Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Hee","family":"Nam","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School , Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9900-2142","authenticated-orcid":false,"given":"Judith C","family":"Maro","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School , Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelle M","family":"Cocoros","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School , Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Rodriguez-Watson","sequence":"additional","affiliation":[{"name":"Reagan-Udall Foundation for the Food and Drug Administration , Washington, District of Columbia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M","family":"Lockhart","sequence":"additional","affiliation":[{"name":"Biologics and Biosimilars Collective Intelligence Consortium , Alexandria, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Platt","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School , Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1609-7420","authenticated-orcid":false,"given":"Robert","family":"Ball","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald J","family":"Dal Pan","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sengwee","family":"Toh","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School , Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"2022111608011522200_ocac153-B1","author":"Food and Drug Administration Amendments Act of 2007","year":"2022"},{"issue":"Suppl 1","key":"2022111608011522200_ocac153-B2","first-page":"1","article-title":"The U.S. Food and Drug Administration\u2019s Mini-Sentinel program: status and direction","volume":"21","author":"Platt","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"2022111608011522200_ocac153-B3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMp1014427","article-title":"Developing the Sentinel System\u2013a national resource for evidence development","volume":"364","author":"Behrman","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"2022111608011522200_ocac153-B4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cpt.320","article-title":"The FDA\u2019s Sentinel Initiative\u2014a comprehensive approach to medical product surveillance","volume":"99","author":"Ball","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"22","key":"2022111608011522200_ocac153-B5","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMp1809643","article-title":"The FDA Sentinel Initiative\u2014an evolving national resource","volume":"379","author":"Platt","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2022111608011522200_ocac153-B6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1740774518812776","article-title":"FDA-Catalyst\u2014using FDA\u2019s Sentinel Initiative for large-scale pragmatic randomized trials: approach and lessons learned during the planning phase of the first trial","volume":"16","author":"Cocoros","year":"2019","journal-title":"Clin Trials"},{"issue":"4","key":"2022111608011522200_ocac153-B7","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/jamiaopen\/ooaa061","article-title":"The FDA MyStudies app: a reusable platform for distributed clinical trials and real-world evidence studies","volume":"3","author":"Wyner","year":"2020","journal-title":"JAMIA Open"},{"issue":"1","key":"2022111608011522200_ocac153-B8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jaip.2020.07.052","article-title":"Risk of psychiatric adverse events among Montelukast users","volume":"9","author":"Sansing-Foster","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2022111608011522200_ocac153-B9","author":"Sentinel Initiative. Sentinel Common Data Model"},{"key":"2022111608011522200_ocac153-B10"},{"issue":"7","key":"2022111608011522200_ocac153-B11","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/pds.5240","article-title":"A COVID-19-ready public health surveillance system: the Food and Drug Administration\u2019s Sentinel System","volume":"30","author":"Cocoros","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022111608011522200_ocac153-B12","author":"Sentinel Initiative"},{"issue":"Suppl 1","key":"2022111608011522200_ocac153-B13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/pds.2336","article-title":"Design considerations, architecture, and use of the Mini-Sentinel distributed data system","volume":"21","author":"Curtis","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022111608011522200_ocac153-B14","author":"Sentinel Initiative"},{"key":"2022111608011522200_ocac153-B15","author":"Sentinel Initiative"},{"issue":"2","key":"2022111608011522200_ocac153-B16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/pds.5112","article-title":"Phosphodiesterase type 5 inhibitor use among pregnant and reproductive-age women in the United States","volume":"30","author":"Liu","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2022111608011522200_ocac153-B17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1148\/radiol.2019190563","article-title":"First-trimester exposure to gadolinium-based contrast agents: a utilization study of 4.6 million U.S. pregnancies","volume":"293","author":"Bird","year":"2019","journal-title":"Radiology"},{"issue":"3","key":"2022111608011522200_ocac153-B18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/pds.4695","article-title":"Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants","volume":"28","author":"Eworuke","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"2022111608011522200_ocac153-B19","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/pds.4185","article-title":"Antiemetic use among pregnant women in the United States: the escalating use of ondansetron","volume":"26","author":"Taylor","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2022111608011522200_ocac153-B20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12884-019-2609-8","article-title":"Use of antidiabetic drugs during pregnancy among U.S. women with livebirth deliveries in the Mini-Sentinel System","volume":"19","author":"Mott","year":"2019","journal-title":"BMC Pregnancy Childbirth"},{"issue":"6","key":"2022111608011522200_ocac153-B21","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/pds.4409","article-title":"Utilization of drugs with pregnancy exposure registries during pregnancy","volume":"27","author":"Illoh","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022111608011522200_ocac153-B22","author":"Kawai","year":"2017"},{"key":"2022111608011522200_ocac153-B23","author":"Suarez","year":"2020"},{"issue":"Suppl 1","key":"2022111608011522200_ocac153-B24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/pds.2242","article-title":"The organizational structure and governing principles of the Food and Drug Administration\u2019s Mini-Sentinel pilot program","volume":"21","author":"Forrow","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022111608011522200_ocac153-B25","author":"Sentinel Initiative"},{"key":"2022111608011522200_ocac153-B26","author":"Sentinel Initiative"},{"key":"2022111608011522200_ocac153-B27","author":"PopMedNet","year":"2012"},{"issue":"2","key":"2022111608011522200_ocac153-B28","first-page":"1213","article-title":"Software-enabled distributed network governance: the PopMedNet experience","volume":"4","author":"Davies","year":"2016","journal-title":"EGEMS (Wash DC)"},{"key":"2022111608011522200_ocac153-B29","author":"Sentinel Initiative"},{"key":"2022111608011522200_ocac153-B30","author":"Sentinel Initiative"},{"issue":"7","key":"2022111608011522200_ocac153-B31","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/jamia\/ocab036","article-title":"Electronic phenotyping of health outcomes of interest using a linked claims-electronic health record database: findings from a machine learning pilot project","volume":"28","author":"Gibson","year":"2021","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"2022111608011522200_ocac153-B32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/amiajnl-2014-002977","article-title":"Toward a science of learning systems: a research agenda for the high-functioning learning health system","volume":"22","author":"Friedman","year":"2015","journal-title":"J Am Med Inform Assoc"},{"key":"2022111608011522200_ocac153-B33","volume-title":"Digital Infrastructure for the Learning Health System: The Foundation for Continuous Improvement in Health and Health Care: Workshop Series Summary","author":"Institute of Medicine","year":"2011"},{"key":"2022111608011522200_ocac153-B34","author":"Sentinel Initiative"},{"key":"2022111608011522200_ocac153-B35","author":"Sentinel Initiative"},{"key":"2022111608011522200_ocac153-B36","author":"Sentinel Initiative"},{"issue":"1","key":"2022111608011522200_ocac153-B37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/pds.5320","article-title":"Use of a mobile app to capture supplemental health information during pregnancy: implications for clinical research","volume":"31","author":"Rothschild","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"2022111608011522200_ocac153-B38","doi-asserted-by":"crossref","first-page":"e2214321","DOI":"10.1001\/jamanetworkopen.2022.14321","article-title":"Effect of mailing educational material to patients with atrial fibrillation and their clinicians on use of oral anticoagulants: a randomized clinical trial","volume":"5","author":"Pokorney","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"7","key":"2022111608011522200_ocac153-B39","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1377\/hlthaff.2014.0121","article-title":"Four health data networks illustrate the potential for a shared national multipurpose big-data network","volume":"33","author":"Curtis","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"2022111608011522200_ocac153-B40"},{"issue":"3","key":"2022111608011522200_ocac153-B41","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11606-018-4697-y","article-title":"Cancer screening results and follow-up using routinely collected electronic health data: estimates for breast, colon, and cervical cancer screenings","volume":"34","author":"Raman","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"2","key":"2022111608011522200_ocac153-B42","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkab009","article-title":"Risk of nonmelanoma skin cancer in association with use of hydrochlorothiazide-containing products in the United States","volume":"5","author":"Eworuke","year":"2021","journal-title":"JNCI Cancer Spectrum"},{"key":"2022111608011522200_ocac153-B43","author":"U.S. Food & Drug Administration"},{"issue":"20","key":"2022111608011522200_ocac153-B44","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1001\/jama.2022.4877","article-title":"Systemic corticosteroid use for COVID-19 in US outpatient settings from April 2020 to August 2021","volume":"327","author":"Bradley","year":"2022","journal-title":"JAMA"},{"key":"2022111608011522200_ocac153-B45","author":"Centers for Disease Control and Prevention Health Alert Network"},{"issue":"5","key":"2022111608011522200_ocac153-B46","doi-asserted-by":"crossref","first-page":"e00512","DOI":"10.1002\/prp2.512","article-title":"Antibiotic dispensing following pediatric visits in the US emergency departments and outpatient settings from 2006 to 2016","volume":"7","author":"Agiro","year":"2019","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"2022111608011522200_ocac153-B47","first-page":"4","article-title":"Learning to share health care data: a brief timeline of influential common data models and distributed health data networks in U.S. Health Care Research","volume":"7","author":"Weeks","year":"2019","journal-title":"EGEMS (Wash DC)"},{"issue":"6","key":"2022111608011522200_ocac153-B48","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1542\/peds.99.6.765","article-title":"Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team","volume":"99","author":"Chen","year":"1997","journal-title":"Pediatrics"},{"issue":"1","key":"2022111608011522200_ocac153-B49","first-page":"1049","article-title":"The HMO research network virtual data warehouse: a public data model to support collaboration","volume":"2","author":"Ross","year":"2014","journal-title":"EGEMS (Wash DC)"},{"issue":"1","key":"2022111608011522200_ocac153-B50","first-page":"7","article-title":"Collaborating on data, science, and infrastructure: the 20-year journey of the cancer research network","volume":"7","author":"Doria-Rose","year":"2019","journal-title":"EGEMS (Wash DC)"},{"issue":"4","key":"2022111608011522200_ocac153-B51","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/amiajnl-2014-002864","article-title":"PCORnet: turning a dream into reality","volume":"21","author":"Collins","year":"2014","journal-title":"J Am Med Inform Assoc"},{"key":"2022111608011522200_ocac153-B52","author":"Sentinel Initiative"},{"key":"2022111608011522200_ocac153-B53"},{"key":"2022111608011522200_ocac153-B54","author":"Sentinel Initiative"},{"key":"2022111608011522200_ocac153-B55","author":"Sentinel Initiative"},{"issue":"4","key":"2022111608011522200_ocac153-B56","first-page":"e134","article-title":"CNODES: the Canadian network for observational drug effect studies","volume":"6","author":"Suissa","year":"2012","journal-title":"Open Med"},{"issue":"S1","key":"2022111608011522200_ocac153-B57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.4722","article-title":"How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias","volume":"29","author":"Platt","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022111608011522200_ocac153-B58","author":"Platt","year":"2017"},{"issue":"1","key":"2022111608011522200_ocac153-B59","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/pds.5168","article-title":"Building an active medical product safety surveillance system in Taiwan: adaptation of the U.S. Sentinel System common data model structure to the National Health Insurance Research Database in Taiwan","volume":"30","author":"Huang","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2022111608011522200_ocac153-B60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40801-017-0124-7","article-title":"Replication of Mini-Sentinel study assessing Mirabegron and cardiovascular risk in non-Mini-Sentinel databases","volume":"5","author":"Simeone","year":"2018","journal-title":"Drugs Real World Outcomes"},{"issue":"6","key":"2022111608011522200_ocac153-B61","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/EDE.0000000000000907","article-title":"Data mining for adverse drug events with a propensity score-matched tree-based scan statistic","volume":"29","author":"Wang","year":"2018","journal-title":"Epidemiology"},{"issue":"11","key":"2022111608011522200_ocac153-B62","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1681\/ASN.2020040526","article-title":"Leveraging the capabilities of the FDA\u2019s Sentinel System to improve kidney care","volume":"31","author":"Adimadhyam","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"2022111608011522200_ocac153-B63","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/pds.5216","article-title":"Health outcomes coding trends in the US Food and Drug Administration\u2019s Sentinel System during transition to International Classification of Diseases-10 coding system: a brief review","volume":"30","author":"Nam","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022111608011522200_ocac153-B64","author":"Sentinel Innovation Center","year":"2021"},{"issue":"5","key":"2022111608011522200_ocac153-B65","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/jamia\/ocaa028","article-title":"Using and improving distributed data networks to generate actionable evidence: the case of real-world outcomes in the Food and Drug Administration\u2019s Sentinel System","volume":"27","author":"Brown","year":"2020","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"2022111608011522200_ocac153-B66","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41746-021-00542-0","article-title":"Broadening the reach of the FDA Sentinel System: a roadmap for integrating electronic health record data in a causal analysis framework","volume":"4","author":"Desai","year":"2021","journal-title":"NPJ Digit Med"},{"key":"2022111608011522200_ocac153-B67","author":"Sentinel Community Building and Outreach Center","year":"2021"},{"issue":"3","key":"2022111608011522200_ocac153-B68","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/jamia\/ocaa196","article-title":"The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment","volume":"28","author":"Haendel","year":"2021","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"2022111608011522200_ocac153-B69","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41746-020-00308-0","article-title":"International electronic health record-derived COVID-19 clinical course profiles: the 4CE Consortium","volume":"3","author":"Brat","year":"2020","journal-title":"NPJ Digit Med"},{"issue":"11","key":"2022111608011522200_ocac153-B70","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/s41366-021-00893-4","article-title":"Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom","volume":"45","author":"Recalde","year":"2021","journal-title":"Int J Obes (Lond)"},{"key":"2022111608011522200_ocac153-B71","author":"European Health Data & Evidence Network"},{"issue":"7","key":"2022111608011522200_ocac153-B72","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/pds.3439","article-title":"The Asian Pharmacoepidemiology Network (AsPEN): promoting multi-national collaboration for pharmacoepidemiologic research in Asia","volume":"22","author":"Andersen","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2022111608011522200_ocac153-B73","first-page":"23","article-title":"Utilizing data consortia to monitor safety and effectiveness of biosimilars and their innovator products","volume":"21","author":"AMCP Task Force on Biosimilar Collective Intelligence Systems","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"2022111608011522200_ocac153-B74","first-page":"1156","article-title":"Harnessing the biologics and biosimilars collective intelligence consortium to evaluate patterns of care","volume":"25","author":"McMahill-Walraven","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"2022111608011522200_ocac153-B75","author":"McMahill-Walraven","year":"2018"},{"issue":"1","key":"2022111608011522200_ocac153-B76","doi-asserted-by":"crossref","first-page":"e00708","DOI":"10.1002\/prp2.708","article-title":"Utilization patterns and characteristics of users of biologic anti-inflammatory agents in a large, US commercially insured population","volume":"9","author":"Mendelsohn","year":"2021","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"2022111608011522200_ocac153-B77","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40801-021-00228-9","article-title":"Patient characteristics and utilization patterns of short-acting recombinant granulocyte colony-stimulating factor (G-CSF) biosimilars compared to their reference product","volume":"8","author":"Mendelsohn","year":"2021","journal-title":"Drugs Real World Outcomes"},{"key":"2022111608011522200_ocac153-B78","author":"Nam","year":"2021"},{"key":"2022111608011522200_ocac153-B79","author":"Nam","year":"2021"},{"issue":"11","key":"2022111608011522200_ocac153-B80","first-page":"1162","article-title":"Descriptive analysis of long- and intermediate-acting insulin and key safety outcomes in adults with type 2 diabetes mellitus","volume":"25","author":"Kent","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"2022111608011522200_ocac153-B81","first-page":"417","article-title":"Incidence of serious infections and design of utilization and safety studies for biologic and biosimilar surveillance","volume":"26","author":"Zhang","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"2022111608011522200_ocac153-B82","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2021.7027","article-title":"BBCIC research network analysis of first-cycle prophylactic G-CSF use in patients treated with high-neutropenia risk chemotherapy [published online ahead of print Aug 16, 2021]","author":"Pawloski","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"2022111608011522200_ocac153-B83","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/pds.4809","article-title":"Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars","volume":"29","author":"Desai","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"2022111608011522200_ocac153-B84","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/pds.4934","article-title":"Capture of biologic and biosimilar dispensings in a consortium of U.S.-based claims databases: utilization of national drug codes and Healthcare Common Procedure Coding System modifiers in medical claims","volume":"29","author":"Zhang","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"2022111608011522200_ocac153-B85","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/pds.4933","article-title":"Mapping from the International Classification of Diseases (ICD) 9th to 10th revision for research in biologics and biosimilars using administrative healthcare data","volume":"29","author":"He","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"2022111608011522200_ocac153-B86","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/pds.4885","article-title":"Barriers and facilitators to conduct high-quality, large-scale safety and comparative effectiveness research: the Biologics and Biosimilars Collective Intelligence Consortium experience","volume":"29","author":"Lockhart","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022111608011522200_ocac153-B87","article-title":"\u2014","author":"Bate","year":"2016"},{"issue":"3","key":"2022111608011522200_ocac153-B88","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/pds.4392","article-title":"Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System\u2019s analytic tools","volume":"27","author":"Sobel","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl 2","key":"2022111608011522200_ocac153-B89","first-page":"932","article-title":"Risk of venous thromboembolism in rheumatoid arthritis patients treated with biologic and non-biologic DMARDS","volume":"77","author":"Maro","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022111608011522200_ocac153-B90","author":"Shinde","year":"2021"},{"key":"2022111608011522200_ocac153-B91","article-title":"\u2014","author":"Connolly","year":"2021"},{"key":"2022111608011522200_ocac153-B92","author":"Huang","year":"2021"},{"issue":"1","key":"2022111608011522200_ocac153-B93","first-page":"e12048","article-title":"Diagnosed prevalence of Alzheimer\u2019s disease and related dementias in Medicare Advantage plans","volume":"12","author":"Jutkowitz","year":"2020","journal-title":"Alzheimers Dement (Amst)"},{"issue":"6","key":"2022111608011522200_ocac153-B94","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1007\/s00520-019-05063-x","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data","volume":"28","author":"Gewandter","year":"2020","journal-title":"Support Care Cancer"},{"issue":"12","key":"2022111608011522200_ocac153-B95","doi-asserted-by":"crossref","first-page":"e0223515","DOI":"10.1371\/journal.pone.0223515","article-title":"Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008\u2013March 2018","volume":"14","author":"Panozzo","year":"2019","journal-title":"PLoS One"},{"key":"2022111608011522200_ocac153-B96","doi-asserted-by":"crossref","first-page":"100515","DOI":"10.1016\/j.conctc.2019.100515","article-title":"Considerations for using distributed research networks to conduct aspects of randomized trials","volume":"17","author":"Marsolo","year":"2020","journal-title":"Contemp Clin Trials Commun"},{"issue":"5","key":"2022111608011522200_ocac153-B97","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/jgs.17013","article-title":"Antidopaminergic-Antiparkinsonian medication prescribing cascade in persons with Alzheimer\u2019s disease","volume":"69","author":"Singh","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"2022111608011522200_ocac153-B98","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1740774520928426","article-title":"Practical challenges in the conduct of pragmatic trials embedded in health plans: lessons of IMPACT-AFib, an FDA-catalyst trial","volume":"17","author":"Garcia","year":"2020","journal-title":"Clin Trials"},{"key":"2022111608011522200_ocac153-B99","doi-asserted-by":"crossref","first-page":"2042098620968310","DOI":"10.1177\/2042098620968310","article-title":"Prescribing cascades in persons with Alzheimer\u2019s disease: engaging patients, caregivers, and providers in a qualitative evaluation of print educational materials","volume":"11","author":"Bloomstone","year":"2020","journal-title":"Ther Adv Drug Saf"},{"issue":"4","key":"2022111608011522200_ocac153-B100","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/pds.4151","article-title":"The feasibility of using multiple databases to study rare outcomes: the potential effect of long-acting beta agonists with inhaled corticosteroid therapy on asthma mortality","volume":"26","author":"Johannes","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"S2","key":"2022111608011522200_ocac153-B101","article-title":"Safety of Trumenba vaccine among pregnant women in the United States: planning and design of a large-scale multi-site observational study","volume":"26","author":"Panozzo","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2022111608011522200_ocac153-B102","doi-asserted-by":"crossref","first-page":"e001003","DOI":"10.1136\/bmjresp-2021-001003","article-title":"Characteristics of new adult users of mepolizumab with asthma in the USA","volume":"8","author":"Wu","year":"2021","journal-title":"BMJ Open Resp Res"},{"key":"2022111608011522200_ocac153-B103","author":"Sentinel Initiative"},{"issue":"8","key":"2022111608011522200_ocac153-B104","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s40264-015-0297-5","article-title":"A comparative assessment of observational medical outcomes partnership and Mini-Sentinel common data models and analytics: implications for active drug safety surveillance","volume":"38","author":"Xu","year":"2015","journal-title":"Drug Saf"},{"key":"2022111608011522200_ocac153-B105","author":"GSK","year":"2020"}],"container-title":["Journal of the American Medical Informatics Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jamia\/article-pdf\/29\/12\/2191\/47027918\/ocac153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jamia\/article-pdf\/29\/12\/2191\/47027918\/ocac153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T08:03:45Z","timestamp":1668585825000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jamia\/article\/29\/12\/2191\/6696156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":105,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,9,12]]},"published-print":{"date-parts":[[2022,11,14]]}},"URL":"https:\/\/doi.org\/10.1093\/jamia\/ocac153","relation":{},"ISSN":["1067-5027","1527-974X"],"issn-type":[{"value":"1067-5027","type":"print"},{"value":"1527-974X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,9,12]]}}}